149 related articles for article (PubMed ID: 37277207)
1. Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.
Craig O; Nigam A; Dall GV; Gorringe K
Cold Spring Harb Perspect Med; 2023 Sep; 13(9):. PubMed ID: 37277207
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
3. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
4. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
6. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
7. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
[TBL] [Abstract][Full Text] [Related]
8. Histotype-specific copy-number alterations in ovarian cancer.
Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
[TBL] [Abstract][Full Text] [Related]
9. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
11. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
12. My approach to and thoughts on the typing of ovarian carcinomas.
McCluggage WG
J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4.
Lassus H; Laitinen MP; Anttonen M; Heikinheimo M; Aaltonen LA; Ritvos O; Butzow R
Lab Invest; 2001 Apr; 81(4):517-26. PubMed ID: 11304571
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer update: lessons from morphology, molecules, and mice.
Cho KR
Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
[TBL] [Abstract][Full Text] [Related]
18. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
19. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
